- Home
- RPRX vs RIVN Comparison
RPRX vs RIVN Comparison
Compare RPRX & RIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPRX | RIVN |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7B | 23.1B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RPRX | RIVN |
|---|---|---|
| Price | $46.15 | $15.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 21 |
| Target Price | ★ $47.75 | $17.89 |
| AVG Volume (30 Days) | 2.7M | ★ 22.4M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | N/A | ★ 34.54 |
| EPS | ★ 1.78 | N/A |
| Revenue | $2,378,193,000.00 | ★ $5,387,000,000.00 |
| Revenue This Year | $38.30 | $33.90 |
| Revenue Next Year | $4.80 | $63.73 |
| P/E Ratio | $25.63 | ★ N/A |
| Revenue Growth | 5.06 | ★ 8.39 |
| 52 Week Low | $29.66 | $10.36 |
| 52 Week High | $47.86 | $22.69 |
Technical Indicators
Market Signals| Indicator | RPRX | RIVN |
|---|---|---|
| Relative Strength Index (RSI) | 58.07 | 46.84 |
| Support Level | $44.94 | $14.62 |
| Resistance Level | $46.14 | $16.17 |
| Average True Range (ATR) | 0.92 | 0.74 |
| MACD | -0.23 | 0.04 |
| Stochastic Oscillator | 39.36 | 22.35 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About RIVN Rivian Automotive Inc.
Rivian is a battery electric vehicle automaker that sells its vehicles in the US and Canada. The company also develops electronic control units and related software for autos in a joint venture with Volkswagen. Rivian has multiple vehicles in its fleet, which include a luxury truck and full-size SUV and a delivery van. The company also plans to begin selling a midsize SUV in 2026. Total deliveries were nearly 52,000 in 2024. Rivian is also developing autonomous driving software to be used in its vehicles.